Cells in living organisms function in an orderly manner by cooperating with surrounding cells while interacting with extracellular proteins. However, in cell culture systems, extracellular proteins are largely absent, making it difficult for cells to function properly and often causing them to exhibit physiological activities that differ from those observed in vivo. Our company conducts research on extracellular matrix proteins located outside the cell, and by applying the findings from this research to cell culture technologies, we aim to contribute to the advancement of regenerative medicine and the realization of alternatives to animal experimentation.
Drug development for neurodegenerative diseases.
Our key product is Enteral Ventilation (EVA) technology, that supplies liquid oxygen to premature babies with serious respiratory problems through Gut-Mediated Oxygen Delivery. The program is at the clinical trial stage.
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.
At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.